流式细胞技术检测乳腺癌骨髓微转移

Detection of bone marrow micrometastasis in breast cancer by CK18, CK19 and significance

目的检测原发性乳腺癌骨髓微转移状况，探讨其与临床病理学指标的关系。方法选取可手术乳腺癌病例82例，术前未经化疗及放疗，抽取骨髓液，应用流式细胞技术，检测骨髓有核细胞中CK18、CK19阳性细胞表达率。结果82例乳腺癌患者骨髓标本中，23例经流式细胞技术检测到CK18^＋、CK19^＋／CD45^-细胞。乳腺癌骨髓微转移的阳性率为28．05％。骨髓微转移的阳性率随临床分期、组织学分级的增加而增高，随激素受体蛋白表达增强而降低。结论原发性乳腺癌可以发生微转移，骨髓微转移与某些临床病理指标有关。

Objective To detect the bone marrow micrometastasis （BMM） of patients with primary breast cancer and determine the relationship between BMM and clinicopathological parameters. Methods Eighty - two cases of breast cancer in our hospital were enrolled, who were not treated by chemotherapy and radiotherapy. The positive rate of CK18 and CK19 expression was detected in bone marrow of patients with primary breast cancer by flow cytometry（ FCM ）. Bone marrow aspiration was done in 1 -3 days preoperation. Results From bone marrow specimens of 82 patients with breast cancer, CK18^＋ ,and CK19^＋/CD45 - cells were detected in 23 cases by FCM. The BMM rate of patients with primary breast cancer was 28.05%. BMM positive rate was increased with the increases in the clinical TNM staging and histological grading,and decreased with the increase in the ER and PR protein in cancer tissues. Conclusion The micrometastasis can take place in the primary breast cancer. BMM is correlated with some clinicopathological parameters.